The number of strong contact and strong contact force of BFRP confined concrete specimens under three coal gangue replacement rates (0%, 50%, 100%). by Qingwen Li (1510687)

Eliminations of dorsal projections in DOM and DOM-A downregulation were due to reduced number of sLNvs and decrease of PDF. by Zhenxing Liu (399809)

(A) Spike patterns of 50 granule cells (GR; top) and Golgi cells (GO; bottom) by Tadashi Yamazaki (40072)

The descriptive statistics for arsenic (As) in micrograms per liter (μg/L), dissolved oxygen (DO; O_2(aq)) in milligrams per liter (mg/L), oxidation-reduction potential (... by Seth H. Frisbie (7821866)

Supplementary Material for: Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland by Haase C.L. (11305977)

“…In practice, the utilization of weight loss drugs is influenced by various factors, including the cost of treatment. We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients’ persistence on treatment, in a real-world setting. …”

Simulations that now also include a <i>symmetric</i> indoors/outdoors model, with a threshold temperature of 17.5C both in spring and in fall. by Sebastian A. Müller (10688740)

Study Data. by Jonathan S. Jahr (2709088)

“…The average heart rate (HR) slowing (3.2 bpm ± 3.9 in the control group, 3.7 bpm ± 3.8 in the dexamethasone group), and maximal HR slowing (5.0 bpm ± 3.9 in the control group, 5.0 bpm ± 3.8 in the dexamethasone group) over the five minutes following sugammadex administration were not significant between groups (average HR slowing p = 0.553, maximal HR slowing p = 0.988). …”

Study outcomes. by Jonathan S. Jahr (2709088)

“…The average heart rate (HR) slowing (3.2 bpm ± 3.9 in the control group, 3.7 bpm ± 3.8 in the dexamethasone group), and maximal HR slowing (5.0 bpm ± 3.9 in the control group, 5.0 bpm ± 3.8 in the dexamethasone group) over the five minutes following sugammadex administration were not significant between groups (average HR slowing p = 0.553, maximal HR slowing p = 0.988). …”

Patient characteristics. by Jonathan S. Jahr (2709088)

“…The average heart rate (HR) slowing (3.2 bpm ± 3.9 in the control group, 3.7 bpm ± 3.8 in the dexamethasone group), and maximal HR slowing (5.0 bpm ± 3.9 in the control group, 5.0 bpm ± 3.8 in the dexamethasone group) over the five minutes following sugammadex administration were not significant between groups (average HR slowing p = 0.553, maximal HR slowing p = 0.988). …”

OCA alone markedly decreases and combined with Gemcitabine or Cisplatin abrogates growth of iCCA xenografts. by S. Di Matteo (6260417)

“…After 4 weeks, when the tumor size was approximately 100 mm³ (T₀) mice were treated with OCA (0.03% w/w, 30 mg/kg) alone or combined with Cisplatin (2.4 mg/Kg in 100 μl) or Gemcitabine (1.05 mg/Kg in 100 μl) for 5 additional weeks. a) Results are expressed as percent increase in tumor volume at different time points. …”

Example of a dependent variable. by Shinya Fukui (19259648)

HBV replication cycle with modeled activity of 1466, a bimodal HBV RNaseH-CAM-I Inhibitor, and other small molecule inhibitors used in this study. by Daniel P. Bradley (10306893)

Supplementary Material for: How Should We Define Postnatal Growth Restriction in Preterm Infants? by Zozaya C. (5419649)

“…<b><i>Results:</i></b> Weight <i>z</i>-scores fell in almost all patients (98.8%), and 44.1% had <i>z</i>-scores <–1.5 at 36 weeks.<b><i></i></b> After adjusting for gestational age and small for gestational age at birth, every 1-point fall in weight <i>z</i>-score was associated with a 5.6 point (95% CI 1.7 to 9.4) decrease in the Mental Developmental Index. …”

Fig 5 Data. by Kevin D. Gaitonde (15411707)

“…We observed a marked decrease in nocturnal locomotion of <i>Opn5</i>^<i>cre</i><i>; Gnas</i>^<i>fl/fl</i> mice at both 28°C and 22°C, but no overall differences in energy expenditure, respiratory exchange, or food and water consumption. …”

Localization of key HH signaling proteins is impaired in <i>Ttbk2</i>^{<i>sca11/gt</i>} cilia. by Emily Bowie (543704)

Comparison of estimated GFR after kidney transplantation according to the dosage of ATG. by Youngmin Ko (3333819)

Subjects:

Raw data of this study (SPSS). by Youngmin Ko (3333819)

Subjects:

Baseline characteristics according to the dosage of antithymocyte globulin. by Youngmin Ko (3333819)

Subjects:

Flow diagram of enrollment, randomization, follow-up, and analysis. by Youngmin Ko (3333819)

Subjects:

Proportion of CD25⁺CD27^- cells among CD3^-CD11b⁺ cells according to the dose of anti-thymocyte globulin. by Youngmin Ko (3333819)

Subjects: